New obesity drug candidate gets first human test in UK
NCT ID NCT07220954
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This early-stage study is testing four different versions of an experimental drug called AZD6234 in 21 healthy adults who are overweight or obese. The goal is to see which formulation gets absorbed best into the blood and to check for any side effects. Participants will receive a single injection of each version in a random order. The study is not designed to test weight loss, but to gather important safety and dosing information for future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGRuddington, NG11 6JS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6234
What this could lead to
If successful, this study could help identify the best formulation of AZD6234 for future weight management trials.
What could go wrong
This is a very early Phase 1 study with only 21 participants, focused on drug absorption and safety, not on weight loss. The drug may not work in larger trials or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.